MannKind Corp. (MNKD)
3.98
-0.03
(-0.75%)
USD |
NASDAQ |
Sep 01, 16:00
3.995
+0.02
(+0.38%)
After-Hours: 20:00
MannKind Research and Development Expense (Annual) : 66.35M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 66.35M |
| December 31, 2024 | 45.89M |
| December 31, 2023 | 31.28M |
| December 31, 2022 | 19.72M |
| December 31, 2021 | 12.31M |
| December 31, 2020 | 6.248M |
| December 31, 2019 | 6.90M |
| December 31, 2018 | 8.737M |
| December 31, 2017 | 14.12M |
| December 31, 2016 | 14.22M |
| December 31, 2015 | 27.46M |
| December 31, 2014 | 101.06M |
| December 31, 2013 | 109.72M |
| Date | Value |
|---|---|
| December 31, 2012 | 101.52M |
| December 31, 2011 | 95.87M |
| December 31, 2010 | 94.96M |
| December 31, 2009 | 124.81M |
| December 31, 2008 | 238.16M |
| December 31, 2007 | 256.84M |
| December 31, 2006 | 191.80M |
| December 31, 2005 | 95.35M |
| December 31, 2004 | 59.27M |
| December 31, 2003 | 45.61M |
| December 31, 2002 | 42.72M |
| December 31, 2001 | 19.76M |
| December 31, 2000 | 20.54M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| United Therapeutics Corp. | 550.00M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Gilead Sciences, Inc. | 5.688B |
| Vertex Pharmaceuticals, Inc. | 3.754B |
| Ocugen, Inc. | 37.36M |